Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, December 4, 2013

Good News for those with MS In Japan: Teva and Takeda Announce Agreement for Glatiramer Acetate for Multiple Sclerosis Treatment

JERUSALEM & OSAKA, Japan--(BUSINESS WIRE)--December 04, 2013-- 
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan. Teva and Takeda are currently working on further agreements in connection with the implementation of this license.
Developed by Teva, glatiramer acetate for injection is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis. It is considered standard treatment for relapsing-remitting multiple sclerosis, and is now approved in 55 countries worldwide. Teva's glatiramer acetate is designated as an orphan drug in Japan, and currently is under development as an Unapproved New Drug by Teva Pharmaceutical K.K., a subsidiary of Teva, at the request of the Japanese Ministry of Health, Labor and Welfare.
Under the terms of the agreement, Teva will grant Takeda commercialization rights in Japan, and Takeda will submit a New Drug Application for registration of glatiramer acetate in Japan. The financial details of the agreement are confidential.
Teva and Takeda will work under close cooperation so that both parties can provide a new treatment option to patients with multiple sclerosis in Japan as early as possible, where the current available therapies are still limited.
About Glatiramer Acetate
……..

To comment - click the comment link shown below
…….
USE OUR SHARE LINKS at the top of this page  - to provide this article to others
……
REMAIN up to date with MS News and Education
Visit: www.msviewsandnews.org  to register
…………………….
.

No comments: